---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-221861"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2022-08-16T23:59:59+00:00"
generated_at: "2026-06-23T23:21:42.868532+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Halozyme upsizes and prices $625M convertible notes due 2028, conversion premium ~30%

## Summary
- $625M aggregate principal; initial purchasers have option for additional $95M.
- 1.00% annual interest rate; conversion price ~$56.02/share, 30% above $43.09 close.
- Use of proceeds: ~$77.6M to exchange existing 2024 notes, up to $200M for share repurchases, $250M term loan repayment.
- Entered capped call transactions with initial cap price ~$75.41/share to reduce dilution.
- Expects to close offering on August 18, 2022.

## SEC filing metadata
- accession: 0001193125-22-221861
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2022-08-16T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000119312522221861/0001193125-22-221861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000119312522221861/d335715d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-221861
- JSON: https://secwatch.observer/filing/0001193125-22-221861.json
- Plain text: https://secwatch.observer/filing/0001193125-22-221861.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.